Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase 1b/2a Study of SLC-391, an AXL Inhibitor, in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Conditions
Interventions
SLC-391
pembrolizumab
Locations
12
United States
Community Health Network
Indianapolis, Indiana, United States
Horizon Verdi Oncology
Lafayette, Indiana, United States
Karmanos Cancer Center
Detroit, Michigan, United States
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Cleveland Clinic
Cleveland, Ohio, United States
Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
Start Date
May 31, 2023
Primary Completion Date
December 1, 2025
Completion Date
December 1, 2025
Last Updated
December 18, 2025
NCT06426511
NCT07144280
NCT05419076
NCT07250477
NCT06639191
NCT06917573
Lead Sponsor
SignalChem Lifesciences Corporation
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions